氨磷汀治疗骨髓增生异常综合征机制的研究进展

Mechanism and Problem of Amifostine in Treating Myelodysplastic Syndromes——Review

骨髓增生异常综合征是起源于造血干/祖细胞的恶性血液病之一,其主要表现为骨髓病态造血,外周血细胞减少。本病主要发生在老年人,其危险因素包括放疗、化疗、苯及其他有机溶剂及免疫抑制剂等。随着医学科学的发展,大量的放疗、化疗及免疫抑制剂用于肿瘤的治疗,控制了肿瘤的发展,但令人担心的是近年来MDS的发生率逐年上升,并且其发病年龄趋向于年轻化。虽然已有大量药物应用于MDS的治疗,但疗效并不乐观,氨磷汀做为泛细胞保护剂也应用于MDS的治疗中。本文就氨磷汀治疗MDS的机制作一综述,并结合目前的相关研究提出了其所面临的问题。

Myelodysplastic syndrome （ MDS ） is one of the most prevalent haematological malignancies originating from haemopoietic stem/progenitor cells. MDS characterized by morbid haematopoiesis of bone marrow and peripheral blood cell reduction and mainly occurs in the eiders. The dangerous factors of MDS include chemotherapy, radiotherapy, benzene, other organic solvent, immune depressants and so on. Following the recent progress of medical sciences, a large number of new regimens of chemotherapy, radiotherapy and immune therapy against carcinomas generate and lead the development of therapeutics for malignancies. It is worried that the incidence of MDS still increases year by year and the patient age becomes younger. Although many agents are used to MDS, curative effect is not as good as expect. Amifostine, a kind of pancytoprotector also used in treatment of MDS. This review summarizes the mechanism of amifostine in MDS therapy which possesses a challenge binding with the current related investigations.